Menu
  • Join
  • Login
  • Contact
 

Search abstracts


New drug targeting and monitoring of bendamustine treatment in patients with chronic lymphocytic leukemia (cll)

  • At: 2004 FIP Congress in New Orleans (USA)
  • Type: Poster
  • By: KOSTOVSKI, Aleksandar (Faculty of Pharmacy, Sofia, Pharmacology and Toxicology, Sofia, Bulgaria)
  • Co-author(s): Konstantinov (Faculty of Pharmacy, Sofia, SOFIA, Bulgaria)
    Alaikov (University Hospital St. Anna, Bulgaria)
    Karaivanova (Faculty of Pharmacy, Sofia, SOFIA, Bulgaria)
  • Abstract:

    Summary

    CLL is characterized by a progressive accumulation of functionally incompetent long-lived CD5+ B-lymphocytes which are monoclonal in origin. Bendamustine is a benzimidazole derivative with two alkylating groups. Fludarabine is a fluorinated adenine derivative belongs to the group of antimetabolites. Erucylphospho-N, N,..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses